Immunotherapy month: T-cells and transplants—avoiding cancer relapse after liver transplantation using AIM Biotech’s organ-on-a-chip assays
To round out our month-long series highlighting research on adoptive T cell immunotherapy, today we’ll take a look at how scientists are modifying T cells to help prevent cancer relapse on liver transplanted patients, harnessing AIM Biotech’s technology. In cases...
Immunotherapy month: Receptor conflict—keeping cancer-killing T cells on-target using AIM Biotech’s organ-on-a-chip assays
This month on AIM’s Voices feed is dedicated to the fascinating research being done on adoptive T cell immunotherapy. Today, we’ll take a look at how scientists used AIM Biotech’s organ-on-a-chip technology to build on previous studies and refine this promising new...
Immunotherapy month: The immune system workaround—suppressing immune checkpoint expression to attack tumors with T cells in AIM Biotech’s organ-on-a-chip
You learned last week how AIM Biotech’s organ-on-a-chip is the perfect model for studying T cell migration to a 3D tumor while examining adoptive T cell immunotherapy. Today, we’ll discuss how scientists used the same technology to discover a major improvement to the...
Immunotherapy month: Tracking T cell migration for use in immunotherapy using a 3D organs-on-a-chip
This month we are exploring the details of adoptive T cell Immunotherapy and how AIM Biotech’s technology facilitated the development of this relevant technique for cancer treatment. In adoptive T cell immunotherapy, the body’s immune T cells are engineered to attack...